SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-18-000095
Filing Date
2018-11-01
Accepted
2018-11-01 16:01:42
Documents
43
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q09302018.htm 10-Q 872980
2 EXHIBIT 10.2 ex102-ceoamendmenttoemploy.htm EX-10.2 21797
3 EXHIBIT 31.1 ex311-ceo302.htm EX-31.1 11030
4 EXHIBIT 31.2 ex312-cfo302.htm EX-31.2 12124
5 EXHIBIT 32 ex32-ceocfo906.htm EX-32 11931
  Complete submission text file 0000891293-18-000095.txt   3444128

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ctic-20180930.xml EX-101.INS 510161
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20180930.xsd EX-101.SCH 22295
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20180930_cal.xml EX-101.CAL 66981
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20180930_def.xml EX-101.DEF 132401
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20180930_lab.xml EX-101.LAB 374673
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20180930_pre.xml EX-101.PRE 206733
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 181153624
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1